Takeda Pharmaceutical

Takeda Pharmaceutical TAK Stock

$21.64   0.979930%
Add to favorites
Exchange
Market Cap
$69.14B
LOW - HIGH [24H]
$21.62 - $21.86
VOLUME [24H]
$1.72M
P/E Ratio
309.14
Earnings per share
$0.07
ISIN
US8740602052
Price   Prediction

Takeda Pharmaceutical Price Chart

Sorry, that's all we've gotfor now...

Takeda Pharmaceutical (TAK) stock price today is 21.64 USD on NYSE (+0.98% on the day). Updated .

Takeda Pharmaceutical TAK Financial and Trading Overview

Takeda Pharmaceutical stock price 21.64 USD
Previous Close 21.12 USD
Open 21.45 USD
Bid 21.44 USD x 710000
Ask 21.75 USD x 820000
Day's Range 21.32 - 21.59 USD
52 Week Range 13.91 - 21.73 USD
Volume 3.73M USD
Avg. Volume 2.64M USD
Market Cap 68.47B USD
Beta (5Y Monthly) 0.077
PE Ratio (TTM) 306.14285
EPS (TTM) 0.07 USD
Forward Dividend & Yield 0.62 (2.88%)
Ex-Dividend Date March 31, 2026
1y Target Est 22.77 USD

TAK Valuation Measures

Enterprise Value 5.01T USD
Trailing P/E 306.14285
Forward P/E 40.433964
PEG Ratio (5 yr expected) 0.49
Price/Sales (ttm) 0.014588371
Price/Book (mrq) 1.4600757
Enterprise Value/Revenue 1.067
Enterprise Value/EBITDA 3.665

Trading Information

Takeda Pharmaceutical Stock Price History

Beta (5Y Monthly) 0.077
52-Week Change 51.55%
S&P500 52-Week Change 13.32%
52 Week High 21.73 USD
52 Week Low 13.91 USD
50-Day Moving Average 19.4 USD
200-Day Moving Average 17.78 USD

TAK Share Statistics

Avg. Volume (3 month) 2.64M USD
Avg. Daily Volume (10-Days) 3M USD
Shares Outstanding 3.19B
Float 3.19B
Short Ratio 1.04
% Held by Insiders 0.11%
% Held by Institutions 3.69%
Shares Short 3.07M
Short % of Float 0.10%
Short % of Shares Outstanding 0.10%

Dividends & Splits

Trailing Annual Dividend Rate 202
Trailing Annual Dividend Yield 956.43%
5 Year Average Dividend Yield 434.99%
Payout Ratio 4.2653
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends March 31, 2026
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End March 31, 2027

Profitability

Profit Margin 0.86%
Operating Margin (ttm) 16.55%
Gross Margin 64.77%
EBITDA Margin 29.11%

Management Effectiveness

Return on Assets (ttm) 3.26%
Return on Equity (ttm) 0.56%

Income Statement

Revenue (ttm) 4.69T USD
Revenue Per Share (ttm) 1482.18 USD
Quarterly Revenue Growth (yoy) 6.70%
Gross Profit (ttm) 3.04T USD
EBITDA 1.37T USD
Net Income Avi to Common (ttm) 40.8B USD
Diluted EPS (ttm) 0.07
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 418.53B USD
Total Cash Per Share (mrq) 131 USD
Total Debt (mrq) 5.36T USD
Total Debt/Equity (mrq) 72.23 USD
Current Ratio (mrq) 1.151
Book Value Per Share (mrq) 14.6773205

Cash Flow Statement

Operating Cash Flow (ttm) 879.67B USD
Levered Free Cash Flow (ttm) 681.38B USD

Profile of Takeda Pharmaceutical

Country United States
State N/A
City Chuo
Address 1-1, Nihonbashi-Honcho 2-chome
ZIP 103-8668
Phone 81 3 3278 2111
Website https://www.takeda.com
Industry Drug Manufacturers - Specialty & Generic
Sector(s) Healthcare
Full Time Employees 47029

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.

Q&A For Takeda Pharmaceutical Stock

What is a current TAK stock price?

Takeda Pharmaceutical TAK stock price today per share is 21.64 USD.

How to purchase Takeda Pharmaceutical stock?

You can buy TAK shares on the NYSE exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Takeda Pharmaceutical?

The stock symbol or ticker of Takeda Pharmaceutical is TAK.

Which industry does the Takeda Pharmaceutical company belong to?

The Takeda Pharmaceutical industry is Drug Manufacturers - Specialty & Generic.

How many shares does Takeda Pharmaceutical have in circulation?

The max supply of Takeda Pharmaceutical shares is 3.19B.

What is Takeda Pharmaceutical Price to Earnings Ratio (PE Ratio)?

Takeda Pharmaceutical PE Ratio is 309.14285000 now.

What was Takeda Pharmaceutical earnings per share over the trailing 12 months (TTM)?

Takeda Pharmaceutical EPS is 0.07 USD over the trailing 12 months.

Which sector does the Takeda Pharmaceutical company belong to?

The Takeda Pharmaceutical sector is Healthcare.

Takeda Pharmaceutical TAK included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us NYSE Composite Index NYA US 24197.79 USD —
-1.32
— — 24152.98 USD — 24520.82 USD — — — —
$2.22T
Total marketcap
$76.2B
Total volume
BTC 58.66%   •   ETH 9.98%
Dominance
Select currency